Fresenius Medical Care North America (FMCNA), the North
American division of
Fresenius Medical Care
), recently revealed that it provides dialysis at night for
patients who are asleep. The company's quality of care at night
matches its day time care at clinics.
The company has set up over 140 night time center-based
dialysis programs in the U.S. It plans to open more nocturnal
centers during 2013.
Dialysis at night, while patients are sleeping, is gaining
popularity. While such dialysis treatment takes a longer period
of time, patients accrue benefit as nocturnal treatment leaves
them free for work or other business during the day. Since
treatment at night spans a longer time, waste material is
gradually removed from the patient, which yields a more gentle
therapy for most recipients.
Dialysis sustains life by removing surplus fluids and
cleansing waste material from the blood stream when a patient's
kidneys stop functioning.
Fresenius is the largest provider of products and services for
patients undergoing dialysis treatment on the planet. The
company's principal competitor in the U.S. is
), which provides dialysis services for patients suffering from
chronic kidney failure or end stage renal disease. Fresenius also
) in certain niches such as the peritoneal dialysis products.
The company continues to register strong operating results in
the North American as well as overseas markets. The integration
of recent acquisitions is also expected to be accretive to
Fresenius' earnings in the near term. However, the contagion of
economic problems remains a matter of concern.
The stock carries a Zacks #3 Rank, which translates into a
short-term Hold rating.
BAXTER INTL (BAX): Free Stock Analysis Report
DAVITA INC (DVA): Free Stock Analysis Report
FRESENIUS MED (FMS): Free Stock Analysis
To read this article on Zacks.com click here.